Media Contact:
Jennifer Martin, (202) 720-8188
Biotechnology has the potential to substantially increase agricultural
productivity, influence markets, and in some cases invent new
uses for traditional crops. However, concerns accompany these
potential benefits. A group of scientists from Virginia examined
the benefits, costs, and risks associated with agricultural
products arising from biotechnology research.
With funding from USDA’s Cooperative State Research,
Education, and Extension Service (CSREES), George Norton and
colleagues at Virginia Polytechnic Institute focused their study
on two crops: tobacco and rice. They chose tobacco because research
is underway to discover pharmaceutical uses for the crop. Rice
was chosen because it is the subject of a large biotechnology
program, with significant implications for U.S. producers, as
well as for producers and low-income consumers in the developing
world.
Norton’s team assessed the costs and benefits of biotechnologies
using economic models. Analyses for tobacco focused on three
pharmaceutical products: glucerebrosidase (an enzyme for treating
Gaucher Disease), human serum albumin (used as a substitute
for blood plasma during surgery), and secretory IgA antibody
(important in preventing tooth decay). The project team determined
that pharmaceutical companies and patent holders would benefit
from biotechnology research in tobacco crops, but the outcome
for farmers and the public would be limited.
A world trade model was used to project the economic consequences
of Asia and the United States implementing biotechnology to
adopt cost-reducing genetically modified rice. The model considered
the potential impacts of insect-, drought-, and herbicide-resistant
genetically modified rice technologies. Projected total benefits
from these three technologies was around $2 billion per year,
but varied regionally; Asian countries benefited from genetically
modified rice, while the United States experienced a small net
loss.
Using a telephone survey, the project team assessed the perceived
social impact from genetically modified crops, specifically
insect-resistant rice and pharmaceutical-producing tobacco.
Results suggest most people had strong feelings, positive or
negative, toward biotechnologies. Willingness to support genetically
modified crops varied with the levels of benefits—consumer
support was greater for plant-based pharmaceuticals than for
genetically modified food products.
Focus groups in the United States, the Philippines, and Bangladesh
elicited stakeholder views or concerns about the potential benefits
and costs of obtaining pharmaceutical products from genetically
modified crops. The focus group also interviewed tobacco manufacturers,
tobacco and rice producers, private biotech firms, environmentalists,
government regulators, clergy, students, World Bank representatives,
university and government researchers, and consumers. The project
team found most citizens of Asian countries were unaware of
biotechnology risk or benefit. U.S. farmers are open to the
idea of genetically modified crops, but fear a backlash that
could negatively affect crop prices.
Educational materials and fact sheets with more details about
project findings are available at http://www.agecon.vt.edu/biotechimpact/.
This project provides beneficial information about the public’s
view of genetically modified agricultural crops in the United
States and abroad. It also explored impacts on these crops of
U.S policies and regulations, and provides greater clarity on
the appropriate roles of the public versus the private sector
in biotechnology research and development.
CSREES funded this research through the Initiative for Future
Agricultural and Food Systems program. Through federal funding
and leadership for research, education and extension programs,
CSREES focuses on investing in science and solving critical
issues affecting people’s daily lives and the nation’s
future. For more information, visit www.csrees.usda.gov.